Dr. Joseph A. Zamaria, Psy.D., ABPP, is Associate Clinical Professor of Psychiatry at the UCSF School of Medicine, Weill Institute for Neurosciences, where he provides clinical, educational, research, and consultative services for the UCSF Department of Psychiatry and Behavioral Sciences.
As an attending psychologist at Langley Porter Psychiatric Hospital & Clinics (LPPHC), Dr. Zamaria maintains an individual and group psychotherapy practice. His clinical interests include psychotherapy integration, psychodynamic therapy, and third-wave cognitive-behavioral therapies such as ACT. He is a licensed clinical psychologist in the state of California. In addition to his California psychology licensure, Dr. Zamaria is board-certified in clinical psychology by the American Board of Professional Psychology (ABPP) and is a Fellow of the American Academy of Clinical Psychology (FAACP). Additionally, he is a member of the Association of Black Psychologists (ABPsi) and is a Founding Member of the American Arab, Middle Eastern, and North African Psychological Association (AMENA-Psy).
Dr. Zamaria is the Associate Program Director for Psychotherapy for the Psychiatry Residency Training Program at UCSF. He is responsible for overseeing residents’ clinical rotations and didactic training in psychotherapy. He also supervises the psychotherapy practices of psychiatry residents and psychology fellows at LPPHC and provides educational leadership and didactic teaching in psychotherapy, having developed and serving as course leader for a curriculum for advanced psychotherapy training.
The focus of Dr. Zamaria's research and scholarly efforts is psychedelic-assisted therapy. He is the principal investigator of a study examining the harm-reduction efficacy of a psychedelic peer-support hotline. Dr. Zamaria also serves as a clinician and researcher in clinical trials examining the potential of psychedelic-assisted psychotherapy to treat a range of conditions. In addition to his research activities, he is on the Editorial Board of the Journal of Psychoactive Drugs and is on the Advisory Board of the Fireside Project.